$12.27 $0.44 (3.7%)

12:17 PM EDT on 04/23/19

Five Prime Therapeutics (NASDAQ:FPRX)

CAPS Rating: 3 out of 5

Current Price $12.27 Mkt Cap $422.7M
Open $11.81 P/E Ratio 0.00
Prev. Close $11.83 Div. (Yield) $0.00 (0.0%)
Daily Range $11.81 - $12.36 Volume 12,793
52-Wk Range $8.62 - $13.81 Avg. Daily Vol.

Caps

How do you think NASDAQ:FPRX will perform against the market?

Add Stock to CAPS Watchlist

All Players

53 Outperform
4 Underperform
 

All-Star Players

22 Outperform
2 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top NASDAQ:FPRX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

healthcarevalue (85.17)
Submitted July 14, 2016

FPRX, market cap 1.2 billion, Return on Invested Capital (ROIC) of impressive 84.69 twelve trailing months. Negligible to zero debt/equity ratio. Price/earnings ratio of 4.9 twelve trailing months. Company description of: Five Prime Therapeutics,… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:FPRX VS S&P 500 (SPY)

NASDAQ:FPRX Summary

Fools bullish on NASDAQ:FPRX are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about FPRX.

Recs

0
Member Avatar TMFBigFrog (95.54) Submitted: 11/20/2018 3:13:44 PM : Outperform Start Price: $11.42 NASDAQ:FPRX Score: -2.74

If its treatments make it through the FDA approval process, its business has a decent chance of shining.

Recs

2
Member Avatar healthcarevalue (85.17) Submitted: 7/13/2016 10:12:10 PM : Outperform Start Price: $43.27 NASDAQ:FPRX Score: -106.89

FPRX, market cap 1.2 billion, Return on Invested Capital (ROIC) of impressive 84.69 twelve trailing months. Negligible to zero debt/equity ratio. Price/earnings ratio of 4.9 twelve trailing months. Company description of: Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes in the United States. -- shows niche area with two different growing disease models.

Recs

2
Member Avatar icanpickm (95.68) Submitted: 4/14/2016 4:41:21 PM : Outperform Start Price: $42.81 NASDAQ:FPRX Score: -114.61

I haven't seen this kind of unique potential in many years. With 1.3 billion market cap, 500 million in cash. A recent 350 million licensing deal with BMY validates their science in my opinion. Their solution is not tied to one cancer or any one method of attack. Its making a new high in light of a shakey biotech sector. The market is agreeing with me for now.

Leaderboard

Find the members with the highest scoring picks in FPRX.

Score Leader

allforone

allforone (27.04) Score: +124.93

The Score Leader is the player with the highest score across all their picks in FPRX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
biotechf 52.54 2/8/2016 Underperform 5Y $31.06 -60.30% +57.71% +118.01 0 Comment
RafaelStock 98.97 8/1/2016 Underperform 5Y $50.77 -75.71% +34.90% +110.61 0 Comment
desertdreams 54.89 4/1/2014 Underperform 5Y $19.67 -37.32% +56.16% +93.47 0 Comment
PeakingDuck 82.96 6/21/2018 Underperform 5Y $17.33 -28.85% +6.80% +35.65 0 Comment
TMFBigFrog 95.54 11/20/2018 Outperform 5Y $11.42 +7.97% +10.71% -2.74 1 Comment
drugtrader 91.35 10/8/2018 Outperform 5Y $13.35 -7.64% +2.07% -9.71 0 Comment
biocqr < 20 8/25/2014 Outperform 5Y $11.02 +11.89% +46.39% -34.50 0 Comment
portefeuille4 99.36 6/4/2018 Outperform 5Y $18.24 -32.40% +6.72% -39.12 0 Comment
portefeuille5 99.33 9/19/2014 Outperform 5Y $11.56 +6.66% +45.86% -39.19 0 Comment
jeepdrew222 62.51 5/31/2018 Outperform 5Y $18.38 -32.92% +7.65% -40.57 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackWedbush 85.98 1/17/2019 Outperform NS $10.95 +12.60% +12.68% -0.08 0 Comment

Advertisement